Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform (INHIBIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02196207

Recruitment Status : Withdrawn (The trial was revised to be two protocols, one Prevention, one Eradication Trials.)

First Posted : July 21, 2014

Last Update Posted : August 20, 2019

Sponsor:

Information provided by (Responsible Party):

Margaret Ragni, University of Pittsburgh

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Withdrawn
Estimated Primary Completion Date :	July 2027
Estimated Study Completion Date :	July 2027

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ragni MV. The effect of emicizumab regimen on haemophilia outcomes. Lancet Haematol. 2019 Jun;6(6):e286-e287. doi: 10.1016/S2352-3026(19)30070-5. Epub 2019 Apr 16.

To Top